Mitogen Activated Protein Kinase Kinase Kinase 5 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) – Pipeline Review, H1 2020’, provides in depth analysis on Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Cardiovascular, Central Nervous System, Immunology, Metabolic Disorders, Toxicology, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Oncology and Undisclosed under development targeting Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)

– The report reviews Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects

– The report assesses Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Angion Biomedica Corp

Calchan Ltd

Chipscreen Biosciences Ltd

Enanta Pharmaceuticals Inc

FronThera US Pharmaceuticals LLC

Gilead Sciences Inc

Kyowa Kirin Co Ltd

Seal Rock Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Terns Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Overview

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Companies Involved in Therapeutics Development

Angion Biomedica Corp

Calchan Ltd

Chipscreen Biosciences Ltd

Enanta Pharmaceuticals Inc

FronThera US Pharmaceuticals LLC

Gilead Sciences Inc

Kyowa Kirin Co Ltd

Seal Rock Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Terns Pharmaceuticals Inc

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Drug Profiles

ANG-4102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-410 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-026856 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-027315 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLPG-3535 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-444217 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-459679 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selonsertib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ASK-1 for Chronic Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ASK1 for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ASK1 for Thrombosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fibrosis, Hematological Diseases and Inflammation – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Unspecified Indication – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ASK1 for Myocardial Infarction, Neurodegenerative Diseases and Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-015 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Dormant Products

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Discontinued Products

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC

2.7.11.25) – Product Development Milestones

Featured News & Press Releases

Nov 08, 2019: PathAI and Gilead show AI-powered pathology research models accurately interpret liver histology in patients with NASH at AASLD 2019

Apr 26, 2019: Gilead’s selonsertib fails in second Phase III trial for NASH

Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-026856 at ILC 2019

Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-027315 at ILC 2019

Feb 13, 2019: Gilead’s selonsertib fails in Phase III STELLAR-4 study for NASH

Nov 09, 2018: Seal Rock Therapeutics advancing differentiated ASK1 inhibitor lead candidate SRT-015 in nonalcoholic steatohepatitis (NASH)

Nov 09, 2018: Gilead Sciences presents data on Selonsertib at The Liver Meeting 2018

Oct 11, 2018: Gilead to present data on Selonsertib at The Liver Meeting 2018

Apr 13, 2018: Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress 2018

Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017

Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016

Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease

Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Angion Biomedica Corp, H1 2020

Pipeline by Calchan Ltd, H1 2020

Pipeline by Chipscreen Biosciences Ltd, H1 2020

Pipeline by Enanta Pharmaceuticals Inc, H1 2020

Pipeline by FronThera US Pharmaceuticals LLC, H1 2020

Pipeline by Gilead Sciences Inc, H1 2020

Pipeline by Kyowa Kirin Co Ltd, H1 2020

Pipeline by Seal Rock Therapeutics Inc, H1 2020

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Pipeline by Terns Pharmaceuticals Inc, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports